Cutaneous cell-mediated immunity (CMI) evoked by dinitrochlorobenzene (DNCB) was evaluated in end-stage renal disease patients on regular haemodialysis and before renal transplantation. Twenty-seven per cent of the patients had suppression of cutaneous CMI as shown by a negative response upon DNCB challenge. We analysed seven factors known or postulated to have an influence on renal allograft rejection for their effects on cutaneous CMI. Age, sex, red blood cell groups, pathogenesis of the underlying kidney disease, and HLA-DRw6 status had no direct effect on the DNCB response. The number of blood transfusions and the duration of haemodialysis were related to a decrease of the DNCB response but were at the same time correlated. By multiple regression analysis it was shown that the number of blood transfusions had a major suppressive effect on the DNCB response, whereas the duration of haemodialysis had a minor suppressive effect if any. Thus the cutaneous CMI evoked by DNCB partly reflects a general CMI response involved in allograft rejection as well. At the same time the effect of blood transfusion on cutaneous CMI restricts the application of the DNCB test for prediction of future renal allograft rejection.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1542293PMC

Publication Analysis

Top Keywords

cutaneous cmi
16
allograft rejection
12
dncb response
12
blood transfusion
8
cutaneous cell-mediated
8
cell-mediated immunity
8
cmi evoked
8
renal allograft
8
number blood
8
blood transfusions
8

Similar Publications

DOCK8 deficiency is the most common cause of autosomal recessive hyper-IgE syndrome (AR-HIES). The clinical spectrum is wide resulting in combined immunodeficiency, atopy, autoimmunity, and malignancies. To study the clinical and molecular profile of 20 patients with DOCK8 deficiency.

View Article and Find Full Text PDF

Durvalumab is an IgG1 monoclonal antibody that has efficacy in many advanced-stage cancers, especially in small-cell lung cancer. The efficacy of durvalumab can be enhanced by chemotherapy. Cutaneous side effects due to treatment with durvalumab are usually self-limiting and easily manageable.

View Article and Find Full Text PDF

One-month daily and three-month weekly rifapentine plus isoniazid are comparable in completion rate and safety for latent tuberculosis infection in non-HIV Population: a randomized controlled trial.

Clin Microbiol Infect

November 2024

Department of Biological Science and Technology, National Chiao Tung University, Hsinchu, Taiwan; Institute of Bioinformatics and Systems Biology, National Chiao Tung University, Hsinchu, Taiwan; Center for Intelligent Drug Systems and Smart Bio-devices, National Chiao Tung University, Hsinchu, Taiwan.

Objectives: The weekly rifapentine plus isoniazid for 3 months (3HP) improves completion rate of latent tuberculosis infection treatment, but flu-like symptoms are common. The novel 1HP regimen, involving daily rifapentine plus isoniazid for 28 days, has demonstrated low toxicity in HIV-infected populations. We aimed to investigate whether 1HP has a lower incidence rate of systemic drug reaction (SDR) compared with 3HP during treatment in non-HIV populations.

View Article and Find Full Text PDF
Article Synopsis
  • Drug-induced lichen planus is a rare skin reaction associated with antitubercular therapy, presenting as flat-topped, reddish-purple bumps on the skin.
  • A case study involved a 63-year-old male with tuberculosis who developed skin lesions after two months on treatment; he was diagnosed with drug-induced lichen planus and managed through the cessation of antitubercular drugs and various medications.
  • The patient showed improvement after rechallenging with certain medications, highlighting the importance of monitoring drug reactions while balancing the risk of worsening tuberculosis.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!